ArticleJournal of neuro-oncology2025
Algorithm-based assessment of T-cell dysfunction and exclusion to forecast ICB sensitivity in pediatric brain ependymoma.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasound-Enhanced Drug Delivery in Pediatric Neuro-Oncology: A New Therapeutic Strategy.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric brain ependymomas are brain tumors difficult to cure despite the advancements in surgery and radiotherapy. Immunotherapies, specifically immune checkpoint blockades (ICB), are traditionally recognized to have a limited efficacy against cold microenvironment as the ones of ependymomas. By employing the Tumor Immune Dysfunction and Exclusion (TIDE) scoring system, this study tries to predict the responsiveness to ICB across molecular subgroups, recurrent/primary presentation and hot vs. cold subtypes.
methodsFour GEO datasets from NCBI public library were selected for this study. In total, 150 RNA-bulk sequences of pediatric ependymomas were analyzed (PF-A = 125, ZFTA-RELA = 23, YAP1 = 2). The TIDE algorithm was applied to quantify cytotoxic T-cell infiltration, dysfunction, and exclusion, estimating ICB response probabilities. Group differences were calculated with Kruskal-Wallis and Fisher's exact tests (p < 0.05).
results60% of ependymomas were predicted ICB responders. ZFTA-RELA tumors showed significantly lower TIDE scores than PF-A (-0.099 ± 0.263 vs. 0.060 ± 0.316; p = 0.008) and a higher response rate (78.3% vs. 56.0%; p = 0.063). RELA-fusion tumors exhibited reduced T-cell dysfunction (-0.235 ± 0.221 vs. - 0.098 ± 0.152; p < 0.001). Recurrent tumors demonstrated lower TIDE scores (-0.070 ± 0.328 vs. 0.081 ± 0.296; p < 0.001) and greater predicted response (75.6% vs. 52.4%; p = 0.011). Responders overall had lower TIDE, dysfunction, and exclusion values (all p < 0.01).
conclusionsPediatric ependymomas are not uniformly immune-silent. ZFTA-RELA and recurrent tumors exhibit a "primed but suppressed" immune phenotype, where the immune machinery is present but functionally restrained, suggesting greater susceptibility to ICB, whereas PF-A tumors remain immune-excluded and may require microenvironmental modulation to achieve immunotherapy benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.